Skip to content
10-K

Annual Report

Inhibitor Therapeutics, Inc. INTI

0001493152-26-012751

← back to feed
Filed
Mar 26, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 25, 2026 172.57M sh
Stock Issued FY 2025 · Dec 31, 2025 215K sh
Stock Issued FY 2025 · Dec 31, 2024 290K sh
Shares Diluted FY 2025 · Dec 31, 2025 172.51M sh
Shares Diluted FY 2025 · Dec 31, 2024 172.26M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$3.23M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$3.23M
Cash And Equivalents FY 2025 · Dec 31, 2025 $2.38M
Cash And Equivalents FY 2025 · Dec 31, 2024 $5.61M
Stockholders Equity FY 2025 · Dec 31, 2025 −$1.29M
Stockholders Equity FY 2025 · Dec 31, 2024 $1.99M
Stockholders Equity FY 2025 · Dec 31, 2023 $5.28M
Current Liabilities FY 2025 · Dec 31, 2025 $766.33K
Current Liabilities FY 2025 · Dec 31, 2024 $709.62K
Total Liabilities FY 2025 · Dec 31, 2025 $3.8M
Total Liabilities FY 2025 · Dec 31, 2024 $3.71M
Current Assets FY 2025 · Dec 31, 2025 $2.45M
Current Assets FY 2025 · Dec 31, 2024 $5.69M
Total Assets FY 2025 · Dec 31, 2025 $2.51M
Total Assets FY 2025 · Dec 31, 2024 $5.69M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.02
Eps Diluted FY 2025 · Dec 31, 2024 −$0.02
Eps Basic FY 2025 · Dec 31, 2025 −$0.02
Eps Basic FY 2025 · Dec 31, 2024 −$0.02
Sga Expense FY 2025 · Dec 31, 2025 $1.73M
Sga Expense restated FY 2025 · Dec 31, 2024 $1.9M
Rd Expense FY 2025 · Dec 31, 2025 $1.7M
Rd Expense restated FY 2025 · Dec 31, 2024 $1.76M
Net Income FY 2025 · Dec 31, 2025 −$3.3M
Net Income FY 2025 · Dec 31, 2024 −$3.34M
Operating Income FY 2025 · Dec 31, 2025 −$3.43M
Operating Income FY 2025 · Dec 31, 2024 −$3.66M